

## Natco Pharma launches generic hepatitis C drug in India

08 May 2017 | News

The company's product is generic version of Gilead Sciences Inc's Epclusa tablets.



Natco Pharma has launched a generic version of sofosbuvir 400 mg/velpatasvir 100 mg tablets, used for treatment of chronic hepatitis C, in India under the brand name Velpanat.

The company's product is generic version of Gilead Sciences Inc's Epclusa tablets.

Epclusa is used to treat adults with chronic hepatitis C genotype 1 to 6 with or without cirrhosis.

Natco priced its generic tablets at an MRP of Rs 18,500 for a bottle of 28 tablets in India.

The company has signed a non-exclusive licensing agreement with Gilead Sciences Inc to manufacture and sell generic versions of its chronic hepatitis C medicines in 101 developing countries.

Natco Pharma Limited was incorporated in Hyderabad in the year 1981 with an initial investment of INR 3.3 million. Natco today has five manufacturing facilities spread across India with dedicated modern research laboratories, capabilities in New Drug Development, etc.